Benign Prostatic Hyperplasia Pipeline Drugs Analysis Report, 2024 Updates FDA Approvals, Clinical Trials, Therapies ... - Barchart
| 086450 Stock | KRW 16,610 30.00 0.18% |
About 61% of DongKook Pharmaceutical's investor base is looking to short. The analysis of current outlook of investing in DongKook Pharmaceutical Co suggests that many traders are alarmed regarding DongKook Pharmaceutical's prospects. The current market sentiment, together with DongKook Pharmaceutical's historical and current headlines, can help investors time the market. In addition, many technical investors use DongKook Pharmaceutical stock news signals to limit their universe of possible portfolio assets.
DongKook |
Benign Prostatic Hyperplasia Pipeline Drugs Analysis Report, 2024 Updates FDA Approvals, Clinical Trials, Therapies ... Barchart
Read at news.google.com
 |
DongKook Pharmaceutical Fundamental Analysis
We analyze DongKook Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DongKook Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DongKook Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
DongKook Pharmaceutical is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
DongKook Pharmaceutical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with DongKook Pharmaceutical stock to make a market-neutral strategy. Peer analysis of DongKook Pharmaceutical could also be used in its relative valuation, which is a method of valuing DongKook Pharmaceutical by comparing valuation metrics with similar companies.
Peers
DongKook Pharmaceutical Related Equities
| 058470 | LEENO Industrial | 2.91 | ||||
| 086900 | Medy Tox | 1.27 |
Complementary Tools for DongKook Stock analysis
When running DongKook Pharmaceutical's price analysis, check to measure DongKook Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DongKook Pharmaceutical is operating at the current time. Most of DongKook Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of DongKook Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DongKook Pharmaceutical's price. Additionally, you may evaluate how the addition of DongKook Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |